You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Infections
  5. COVID-19

FebriDx for C-reactive protein and myxovirus resistance protein A testing

  • Medtech innovation briefing
  • Reference number: MIB224
  • Published:  26 August 2020

Download (PDF)
  • Overview
  • Summary
  • The technology
  • Regulatory information
  • Equality considerations
  • Clinical and technical evidence
  • Expert comments
  • Expert commentators
  • Development of this briefing

Overview

NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing.

What are MIBs?

This advice updates and replaces medtech innovation briefing 114.


Next page Summary
Back to top